Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

1091200

USP

Captopril

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

N-[(S)-3-Mercapto-2-methylpropionyl]-L-prolin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C9H15NO3S
CAS-Nummer:
62571-86-2
Molekulargewicht:
217.29
Beilstein:
477887
MDL-Nummer:
MFCD00168073
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329749226
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

captopril

Hersteller/Markenname

USP

mp (Schmelzpunkt)

104-108 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChIKey

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Angaben zum Gen

human ... ACE(1636)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Captopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Captopril and Hydrochlorothiazide Tablets
  • Captopril Compounded Oral Solution
  • Captopril Compounded Oral Suspension
  • Captopril Tablets

Biochem./physiol. Wirkung

Angiotensin Converting Enzyme-Hemmer. Hemmt die Bildung von Angiotensin II, einem bioaktiven Peptid, das die Angionese stimuliert und die Mikrogefäßdichte erhöht.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1091221

Captoprildisulfid, United States Pharmacopeia (USP) Reference Standard

C0430000

Captopril, European Pharmacopoeia (EP) Reference Standard

Y0000435

Captopril Unreinheit E, European Pharmacopoeia (EP) Reference Standard

Y0001182

Captopril für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril Unreinheit D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril Unreinheit B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril Unreinheit C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril Unreinheit J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captoprildisulfid, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H341,H360F

Gefahreneinstufungen

Muta. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Marie-Claude Racine et al.
Current hypertension reports, 4(3), 245-249 (2002-05-11)
With the introduction of more simple screening tests such as the aldosterone/renin ratio, the detection rate of primary aldosteronism has increased considerably. Until now, no reference values have been available for reporting the aldosterone/renin ratio using plasma aldosterone values expressed
A Schattner et al.
The American journal of the medical sciences, 322(4), 236-240 (2001-10-27)
Two elderly patients, treated with captopril for left ventricular dysfunction and diabetes, developed severe cholestatic jaundice for which no alternative explanation could be found. The jaundice resolved completely after discontinuation of the drug. A review of the literature identifies a
A O Nur et al.
International journal of pharmaceutics, 194(2), 139-146 (2000-02-29)
The development of oral sustained or controlled release dosage form of captopril has been an interested topic of research for a long period of time. Difficulties encountered with such topic based on the fact that the drug is freely water
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.